Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently
We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other ...
Entropy Technologies LP Purchases New Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the ...
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00 at Evercore ISI
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target hoisted by Evercore ISI from $33.00 to $45.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently ...
Travere Therapeutics price target raised to $47 from $45 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...
Travere therapeutics officer sells shares worth over $1.35 million
Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial ...
Travere therapeutics chief medical officer sells $60k in stock
Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), a $2 billion market cap biopharmaceutical company whose stock has surged 190% over the past year, recently sold 2,568 shares of the company's ...
Travere Therapeutics (TVTX) Gets a Buy from Scotiabank
Scotiabank analyst Greg Harrison maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of ...